Bristol-Myers Squibb Company

- The company plans to take on additional debt in 2024 to finance acquisitions of Karuna and RayzeBio. - Despite this new debt, the company expects strong cash flow to repay approximately $10 billion of debt over the next two years, aiming to improve leverage. - There is no mention of any new equity fundraising in the provided excerpts. - The company emphasizes maintaining strong operating margins and financial discipline while investing in growth and managing capital allocation.

- Business development and capital allocation remain a priority, with a focus on executing recent deals and continuing to seek strategic bolt-on opportunities and partnerships. - Planned acquisitions of Karuna and RayzeBio will be financed partly by taking on additional debt this year. - The company plans to repay approximately $10 billion of debt over the next two years to improve leverage. - Investments continue in pipeline and product launches, notably supporting products like Camzyos, Sotyktu, and new launches such as KarXT. - Operating expenses will increase slightly to absorb costs related to recent acquisitions (Karuna, RayzeBio) and reallocation for efficiency initiatives. - The focus is on commercial execution of new product launches and expanding growth portfolio through innovation that makes strategic and financial sense.

- 2024 revenue expected to increase in a low single-digit range on an underlying basis, reflecting confidence in growth portfolio momentum. - Growth driven by expanding sales of Opdivo and recently launched products, despite more modest growth pace for Opdivo compared to last year. - Strong growth anticipated for Eliquis in the U.S. through the end of 2025. - Sales growth projected for newer products such as Reblozyl, Breyanzi (with approval and supply expansions), Camzyos, and Sotyktu as commercial and international access improves. - Sotyktu expected to grow from improved payer access (e.g., ESI, Cigna), with prescription volumes projected to roughly double by Q4 2024 and continue momentum into 2025. - Reblozyl sales to continue strong growth in first-line MDS in the U.S. and internationally, including Japan and Europe. - Potential for sustained top-tier growth in the back half of the decade (around 2028 and beyond) driven by pipeline and new launches. - Modest short-term growth period with transition towards sustainable growth in the longer term.

- Bristol Myers Squibb expects revenue growth in the low single-digit range for 2024, driven by momentum in their growth portfolio including Opdivo and recently launched products. - Gross margin is projected around 74%, reflecting sales mix evolution and nonrecurrence of prior year hedging gains. - Selling, General & Administrative (SG&A) expenses are expected to grow in the low single-digit range due to new acquisitions and strategic investments. - Operating income and expenses (OI&E) are projected to yield approximately $250 million of income, reflecting PD-1 royalty streams and Mirati acquisition financing costs. - The effective tax rate is anticipated near 17.5%, influenced by the nonrecurrence of certain tax benefits and Pillar 2 impact. - Non-GAAP earnings per share (EPS) guidance for 2024 is between $7.10 and $7.40. - Anticipated dilutive impact from acquisitions: Karuna (~$0.30 EPS) and RayzeBio (~$0.13 EPS). - The company remains focused on operational efficiencies, investing for growth, and maintaining high productivity.

- Sotyktu Bridge to commercial conversion is progressing well, with a 40% sequential net sales increase excluding clinical trial orders. - Expected to reach roughly 20,000 paid prescriptions by Q4 2024, about double the volume earlier in the year. - Active negotiations ongoing with payers to secure improved access and expand coverage beyond current 65 million lives (including CVS, ESI, and Cigna). - Reblozyl sales accelerating, with strong U.S. first-line MDS launch and international rollouts ongoing, including Japan and expected Europe approval H1 2024. - Orders for new products like Augtyro have started with initial wholesaler stocking in Q4. - Business expects continued demand and volume growth across growth portfolio products. - No explicit numeric orderbook figures disclosed; focus is on ongoing prescription volume growth and payer negotiations to expand market access.